← Eichor
Condition: Potentially Resectable Stage Ii Iiia Nsclc Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Potentially Resectable Stage Ii Iiia Nsclc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage II
Phase 3 · 1 location(s) · Guangdong Provincial People's Hospital · NCT07016126Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC
Phase 1/Phase 2 · 1 location(s) · Yonsei University · NCT03694236
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.